Form 8-K - Current report:
SEC Accession No. 0001193125-23-135979
Filing Date
2023-05-04
Accepted
2023-05-04 16:31:00
Documents
12
Period of Report
2023-05-04
Items
Item 1.01: Entry into a Material Definitive Agreement
Item 2.03: Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant

Document Format Files

Seq Description Document Type Size
1 8-K d306647d8k.htm   iXBRL 8-K 24650
  Complete submission text file 0001193125-23-135979.txt   146638

Data Files

Seq Description Document Type Size
2 XBRL TAXONOMY EXTENSION SCHEMA lnth-20230504.xsd EX-101.SCH 2853
3 XBRL TAXONOMY EXTENSION LABEL LINKBASE lnth-20230504_lab.xml EX-101.LAB 17994
4 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE lnth-20230504_pre.xml EX-101.PRE 11263
6 EXTRACTED XBRL INSTANCE DOCUMENT d306647d8k_htm.xml XML 3355
Mailing Address 331 TREBLE COVE ROAD NORTH BILLERICA MA 01862
Business Address 331 TREBLE COVE ROAD NORTH BILLERICA MA 01862 978 671-8001
Lantheus Holdings, Inc. (Filer) CIK: 0001521036 (see all company filings)

EIN.: 352318913 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-36569 | Film No.: 23889293
SIC: 2835 In Vitro & In Vivo Diagnostic Substances